Qilu Pharmaceutical Co., Ltd.

A newly approved, homegrown once-weekly GLP-1 receptor agonist is seeking to disrupt a diabetes space in China currently dominated by Novo Nordisk’s same-class global blockbuster Ozempic (semaglutide)

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou

As China’s national anti-corruption campaign enters a new stage and goes deep into the local level, physicians in the country are becoming increasingly cautious about issuing prescriptions for high-va

The House Energy and Commerce Committee Republican leadership is asking the US Food and Drug Administration for a wealth of information about its approach to inspections in India and China coming out